• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 5

Episode 5 - Pharmacoeconomic Considerations

Video

During this discussion, Jeffrey D. Dunn, PharmD, MBA, explains how the rapid development of specialty drugs for the treatment of castration-resistant prostate cancer (CRPC) has increased the amount of pharmacoeconomic spending in the United States.

Because there are several options available, and because clinicians have different treatment preferences, Michael Kolodziej, MD, discusses why it is necessary to determine a proper sequencing plan before administering treatment.

Raoul S. Concepcion, MD, agrees that drug sequencing is a major challenge. However, he believes that because so many treatment options are available, clinicians need to individualize therapy when treating patients with CRPC.

Dr Dunn, Dr Concepcion, and David Quinn, MD, review the costs of new agents and discuss why it is important for insurers to provide coverage toward research that tests drug sequencing.


Related Videos
Dr Xin Hu
Elizabeth Jones, MD, FAAD.
Tiffany Meng, PharmD, oncology pharmacist with UCSF Health
Rachel Rohaidy, MD
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
Screenshot of an interview with Shaun McKenzie, MD
Jeffrey Stark, MD, vice president and head of medical immunology at UCB.
Sabarish Ayyappan, MD
Dr Maria DeYoreo
Screenshot of an interview with Shaun McKenzie, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.